Apitegromab
- Generic Name
- Apitegromab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2278276-46-1
- Unique Ingredient Identifier
- UZ54216N0Y
- Background
Apitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
- Associated Conditions
- -
- Associated Therapies
- -
Scholar Rock's Phase 3 SAPPHIRE Study Of Apitegromab In SMA Meets Primary Goal; Stock Surges
Scholar Rock's Phase 3 SAPPHIRE study met primary goal, showing significant motor function improvement in SMA patients treated with apitegromab. The treatment was well-tolerated, and no new safety issues were found. The company plans to submit a U.S. BLA and EU MAA in Q1 2025.
Spinal Muscular Atrophy Clinical Trials 2024 (Updated): EMA
DelveInsight's 'Spinal Muscular Atrophy Pipeline Insight, 2024' report details 18+ companies developing 20+ therapies, including key players like Scholar Rock, Biogen, and Roche. The report covers clinical trials, MOA, ROA, recent developments, and emerging therapies like ACTX-401, Apitegromab, and GYM329, expected to impact the SMA market.
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates
Aldeyra's shares fell after FDA identified issues with its NDA for reproxalap, requiring additional studies. Annovis Bio's Alzheimer’s study on buntanetap showed positive interim results. Scholar Rock plans to expand into cardiometabolic disorders with SRK-439. Evelo's psoriasis study failed, halting EDP2939 development. Amylyx faces EU setback for ALS treatment AMX0035, focusing on phase III study results.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath